Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: Results from a multi-institutional phase 1 study

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 540-545

  Corn, Paul G ^a   Song, Danny Y ^b   Heath, Elisabeth ^c   Maier, Jordan ^c   Meyn, Raymond ^a   Kuban, Deborah ^a   DePetrillo, Thomas A ^d   Mathew, Paul ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; DRUG INTERACTIONS; IONIZING RADIATION; PATIENT TREATMENT; RADIATION; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS INHIBITORS; EXTERNAL BEAM RADIATION THERAPY; GROWTH FACTOR RECEPTORS; HIGH-RISK PROSTATE CANCERS; PLATELET-DERIVED GROWTH FACTOR RECEPTORS; PROSTATE SPECIFIC ANTIGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

RADIOTHERAPY;

BICALUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; SUNITINIB; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; NITRILE; PYRROLE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROSTATE ADENOCARCINOMA; RADIATION DOSE; SEMINAL VESICLE; THROMBOCYTOPENIA; VERY ELDERLY; ADENOCARCINOMA; BLOOD; CANCER GRADING; CANCER STAGING; DRUG INTERACTION; FEASIBILITY STUDY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RADIATION EXPOSURE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG INTERACTIONS; FEASIBILITY STUDIES; GOSERELIN; HUMANS; INDOLES; LEUPROLIDE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NITRILES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRROLES; RADIOTHERAPY, INTENSITY-MODULATED; SEMINAL VESICLES; TOSYL COMPOUNDS;

MLCS; MLOWN;

EID: 84880645173     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.12.029     Document Type: Article

References (20)

1. Paquette EL, Sun L, Paquette LR, et al. Improved prostate cancerspecific survival and other disease parameters: Impact of prostatespecific antigen testing. Urology 2002;60:756-759.
2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002;360:103-106.
3. Pilepic MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive therapy in prostate carcinomadlong term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285-1290.
4. Coen JJ, Zietman AL, Thakral H, et al. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 2002;20:3199-3205.
5. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293:293-297.
6. Denekamp J, Hobson B. Endothelial-cell proliferation in experimental tumours. Br J Cancer 1982;46:711-720.
7. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res 2003;9:1957-1971.
8. Teicher A, Dupis N, Kusumoto T, et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 1995;2:269-276.
9. Rockwell S, Dobrucki IT, Kim EY, et al. Hypoxia and radiation therapy: Past history, ongoing research and future promise. Curr Mol Med 2009;9:442-458.
10. Scheuneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-4016.
11. Brooks C, Sheu T, Bridges K, et al. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as radiosensitizer for human prostate cancer. Radiat Oncol 2012;7:154.
12. Timke C, Zieher H, Roth A, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008;14:2210-2219.
13. Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004;43:855-878.
14. Roach M 3rd, Hanks G, Thames H Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
15. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763-773.
16. Vuky J, Pham HT, Warren S, et al. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:e609-e615.
17. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011;103:645-661.
18. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18: 1765-1773.
19. Crook JM, Malone S, Perry G, et al. Twenty-four month post-radiation biopsies are strongly predictive of 7-year disease-free survival. Cancer 2009;115:673-679.
20. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Eng J Med 2011; 365:107-118.